COVID-19疫情期间临床试验的开展——协作试验网络的应对
COVID-19疫情对医疗系统提出空前需求,迫使重新评估临床试验的实施与可行性。澳大利亚肾脏试验网络(AKTN)作为开展研究者发起的全球临床试验的成熟协作研究组,需在疫情期间高效响应并适应变化。关键优先事项包括确保患者和工作人员安全、试验完整性以及肾脏照护社区的可持续性,并已开发新资源以支持结构化的审查和应急计划。
要点
- 疫情期间临床试验需优先保障患者与工作人员安全。
- 维护试验完整性和研究网络可持续性是关键挑战。
- AKTN开发了结构化审查与应急计划资源以应对疫情。
核心结论
- COVID-19疫情迫使临床试验重新评估实施方式,AKTN通过协作网络响应并优先保障安全、完整性和可持续性。
研究设计与样本
- 描述性文章,介绍AKTN在COVID-19疫情期间的应对策略与资源开发。
主要发现
- AKTN将患者和工作人员安全、试验完整性及网络可持续性作为关键优先事项。
- AKTN开发了新资源以支持疫情期间及之后试验活动的结构化审查和应急计划。
临床怎么用
- 临床试验团队可参考AKTN的结构化审查和应急计划资源来调整试验活动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.
引用
- Robison L, Cho Y, Viecelli AK, et al. Conducting clinical trials during the COVID-19 pandemic-a collaborative trial network response. Trials. 2021. PMID: 33853661. doi:10.1186/s13063-021-05200-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。